ALS-AAV9

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameALS-AAV9

Drug Alias Nameamyotrophic lateral sclerosis gene therapy (RegenX Biosciences)adeno-associated virus vector-9 based gene therapy (RegenX Biosciences)ALS-AAV9

ClassificationBiologics

Mechanisms of ActionNeuroprotectants

TargetsUpdating

Therapy Area/IndicationsAmyotrophic Lateral Sclerosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesRegenxbio Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesRegenxbio Inc

Active IndicationsN/A

Inactive IndicationsAmyotrophic Lateral Sclerosis

Other Information

ATC CodeN/A